{"id":"https://openalex.org/W7213497904","doi":"https://doi.org/10.1177/20499361261483967","title":"Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales","display_name":"Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales","publication_year":2026,"publication_date":"2026-09-01","ids":{"openalex":"https://openalex.org/W7213497904","doi":"https://doi.org/10.1177/20499361261483967","pmid":"https://pubmed.ncbi.nlm.nih.gov/42973728","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13724907"},"language":"en","primary_location":{"id":"doi:10.1177/20499361261483967","doi":"https://doi.org/10.1177/20499361261483967","is_oa":true,"landing_page_url":"https://doi.org/10.1177/20499361261483967","pdf_url":null,"source":{"id":"https://openalex.org/S4210217046","display_name":"Therapeutic Advances in Infectious Disease","issn_l":"2049-9361","issn":["2049-9361","2049-937X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Infectious Disease","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1177/20499361261483967","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051779373","display_name":"Klodeta Kura","orcid":"https://orcid.org/0000-0002-0008-1440","observed_orcids":["https://orcid.org/0000-0002-0008-1440"]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Klodeta Kura","raw_affiliation_strings":["MSD (UK) Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MSD (UK) Ltd","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045945600","display_name":"Colleen Burgess","orcid":"https://orcid.org/0000-0003-0393-0767","observed_orcids":["https://orcid.org/0000-0003-0393-0767"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Colleen Burgess","raw_affiliation_strings":["Merck & Co., Inc"],"raw_orcid":"https://orcid.org/0000-0003-0393-0767","affiliations":[{"raw_affiliation_string":"Merck & Co., Inc","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018817243","display_name":"Ian R. Matthews","orcid":"https://orcid.org/0000-0001-6175-6512","observed_orcids":["https://orcid.org/0000-0001-6175-6512"]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian R. Matthews","raw_affiliation_strings":["MSD (UK) Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MSD (UK) Ltd","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049698253","display_name":"S. Garba","orcid":"https://orcid.org/0000-0003-1622-1951","observed_orcids":["https://orcid.org/0000-0003-1622-1951"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Salisu M. Garba","raw_affiliation_strings":["Merck & Co., Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100445448","display_name":"Dawei Wang","orcid":"https://orcid.org/0000-0002-7785-128X","observed_orcids":["https://orcid.org/0000-0002-7785-128X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dawei Wang","raw_affiliation_strings":["Merck & Co., Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5130232653","display_name":"John C. Lang","orcid":"https://orcid.org/0000-0002-1770-2995","observed_orcids":["https://orcid.org/0000-0002-1770-2995"]},"institutions":[{"id":"https://openalex.org/I4210095507","display_name":"Merck Canada Inc. (Canada)","ror":"https://ror.org/00rz3ed53","country_code":"CA","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210095507"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"John C. Lang","raw_affiliation_strings":["Health Economic and Decision Sciences, Merck Canada Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economic and Decision Sciences, Merck Canada Inc","institution_ids":["https://openalex.org/I4210095507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052278265","display_name":"Dionysios Ntais","orcid":"https://orcid.org/0000-0002-5853-5548","observed_orcids":["https://orcid.org/0000-0002-5853-5548"]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dionysios Ntais","raw_affiliation_strings":["MSD (UK) Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MSD (UK) Ltd","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009705578","display_name":"Yao-Hsuan Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Yao-Hsuan Chen","raw_affiliation_strings":["MSD (UK) Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MSD (UK) Ltd","institution_ids":["https://openalex.org/I4210087189"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5051779373"],"corresponding_institution_ids":["https://openalex.org/I4210087189"],"apc_list":{"value":2800,"currency":"USD","value_usd":2800},"apc_paid":{"value":2800,"currency":"USD","value_usd":2800},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.64107895,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":null,"first_page":"20499361261483967","last_page":"20499361261483967"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.008500000461935997,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13770","display_name":"Pediatric health and respiratory diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/respiratory-syncytial-virus","display_name":"respiratory syncytial virus","score":0.8970000147819519},{"id":"https://openalex.org/keywords/clesrovimab","display_name":"clesrovimab","score":0.9819999933242798},{"id":"https://openalex.org/keywords/rsv-prophylaxis","display_name":"RSV prophylaxis","score":0.8119999766349792},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8859999775886536},{"id":"https://openalex.org/keywords/infants","display_name":"infants","score":0.6389999985694885},{"id":"https://openalex.org/keywords/lower-respiratory-tract-infection","display_name":"lower respiratory tract infection","score":0.9319999814033508},{"id":"https://openalex.org/keywords/palivizumab","display_name":"palivizumab","score":0.9039999842643738},{"id":"https://openalex.org/keywords/nirsevimab","display_name":"nirsevimab","score":1.0},{"id":"https://openalex.org/keywords/maternal-immunization","display_name":"maternal immunization","score":0.906000018119812},{"id":"https://openalex.org/keywords/catch-up-vaccination","display_name":"catch-up vaccination","score":0.6650000214576721},{"id":"https://openalex.org/keywords/health-economic-impact","display_name":"health economic impact","score":0.6520000100135803},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8379999995231628},{"id":"https://openalex.org/keywords/england-and-wales","display_name":"England and Wales","score":0.6439999938011169}],"concepts":[{"id":"https://openalex.org/C2778644256","wikidata":"https://www.wikidata.org/wiki/Q412765","display_name":"Palivizumab","level":3,"score":0.8671000003814697},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8519999980926514},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.5212000012397766},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.49950000643730164},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.47859999537467957},{"id":"https://openalex.org/C188897","wikidata":"https://www.wikidata.org/wiki/Q5333508","display_name":"Economic impact analysis","level":2,"score":0.4677000045776367},{"id":"https://openalex.org/C2776012195","wikidata":"https://www.wikidata.org/wiki/Q754447","display_name":"Respiratory tract infections","level":3,"score":0.4413999915122986},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.43050000071525574},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3675000071525574},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.34150001406669617},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.334199994802475},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.323199987411499},{"id":"https://openalex.org/C2780665704","wikidata":"https://www.wikidata.org/wiki/Q959298","display_name":"Intervention (counseling)","level":2,"score":0.3163999915122986},{"id":"https://openalex.org/C108650721","wikidata":"https://www.wikidata.org/wiki/Q1783253","display_name":"Counterfactual thinking","level":2,"score":0.3116999864578247},{"id":"https://openalex.org/C145096142","wikidata":"https://www.wikidata.org/wiki/Q5333450","display_name":"Economic cost","level":2,"score":0.30790001153945923},{"id":"https://openalex.org/C524218345","wikidata":"https://www.wikidata.org/wiki/Q31218","display_name":"Health economics","level":3,"score":0.2996000051498413},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.2992999851703644},{"id":"https://openalex.org/C2781445406","wikidata":"https://www.wikidata.org/wiki/Q24802277","display_name":"Pneumovirinae","level":5,"score":0.2944999933242798},{"id":"https://openalex.org/C2779234561","wikidata":"https://www.wikidata.org/wiki/Q11995","display_name":"Pregnancy","level":2,"score":0.29339998960494995},{"id":"https://openalex.org/C116675565","wikidata":"https://www.wikidata.org/wiki/Q3241045","display_name":"Outbreak","level":2,"score":0.2919999957084656},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2825999855995178},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.28220000863075256},{"id":"https://openalex.org/C89623803","wikidata":"https://www.wikidata.org/wiki/Q12184","display_name":"Pandemic","level":5,"score":0.28200000524520874},{"id":"https://openalex.org/C26831200","wikidata":"https://www.wikidata.org/wiki/Q16963953","display_name":"Marginal structural model","level":3,"score":0.27959999442100525},{"id":"https://openalex.org/C127454912","wikidata":"https://www.wikidata.org/wiki/Q942582","display_name":"Cost\u2013benefit analysis","level":2,"score":0.27790001034736633},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.27320000529289246},{"id":"https://openalex.org/C2776399701","wikidata":"https://www.wikidata.org/wiki/Q3631290","display_name":"Lower respiratory tract infection","level":4,"score":0.27300000190734863},{"id":"https://openalex.org/C2778821649","wikidata":"https://www.wikidata.org/wiki/Q424227","display_name":"Bronchiolitis","level":3,"score":0.2678000032901764},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.2676999866962433},{"id":"https://openalex.org/C2778299150","wikidata":"https://www.wikidata.org/wiki/Q7441897","display_name":"Season of birth","level":2,"score":0.26109999418258667},{"id":"https://openalex.org/C2776125615","wikidata":"https://www.wikidata.org/wiki/Q18391886","display_name":"Economic evaluation","level":2,"score":0.26089999079704285},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.2558000087738037}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.1177/20499361261483967","doi":"https://doi.org/10.1177/20499361261483967","is_oa":true,"landing_page_url":"https://doi.org/10.1177/20499361261483967","pdf_url":null,"source":{"id":"https://openalex.org/S4210217046","display_name":"Therapeutic Advances in Infectious Disease","issn_l":"2049-9361","issn":["2049-9361","2049-937X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Infectious Disease","raw_type":"journal-article"},{"id":"doi:10.64898/2025.12.03.25341225","doi":"https://doi.org/10.64898/2025.12.03.25341225","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2025.12.03.25341225","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2025/12/04/2025.12.03.25341225.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:13724907","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13724907/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13724907/pdf/10.1177_20499361261483967.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ther Adv Infect Dis","raw_type":"Text"},{"id":"pmid:42973728","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42973728","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic advances in infectious disease","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:f67436eb107641119b6ab627936df0c0","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/f67436eb107641119b6ab627936df0c0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Therapeutic Advances in Infectious Disease, Vol 13 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1177/20499361261483967","doi":"https://doi.org/10.1177/20499361261483967","is_oa":true,"landing_page_url":"https://doi.org/10.1177/20499361261483967","pdf_url":null,"source":{"id":"https://openalex.org/S4210217046","display_name":"Therapeutic Advances in Infectious Disease","issn_l":"2049-9361","issn":["2049-9361","2049-937X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Infectious Disease","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7213497904.pdf","grobid_xml":"https://content.openalex.org/works/W7213497904.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1989620354","https://openalex.org/W2063095964","https://openalex.org/W2079720526","https://openalex.org/W2089657822","https://openalex.org/W2145759685","https://openalex.org/W2533155835","https://openalex.org/W2558274900","https://openalex.org/W2727509207","https://openalex.org/W2741939284","https://openalex.org/W2753817014","https://openalex.org/W2917963204","https://openalex.org/W2939752502","https://openalex.org/W2964871094","https://openalex.org/W2980647784","https://openalex.org/W2985850848","https://openalex.org/W3100996326","https://openalex.org/W3107159225","https://openalex.org/W4205915886","https://openalex.org/W4214852692","https://openalex.org/W4226165957","https://openalex.org/W4291164944","https://openalex.org/W4295222478","https://openalex.org/W4307896714","https://openalex.org/W4313887251","https://openalex.org/W4318766800","https://openalex.org/W4362636468","https://openalex.org/W4386121391","https://openalex.org/W4390662601","https://openalex.org/W4391888934","https://openalex.org/W4406950201","https://openalex.org/W4406954360","https://openalex.org/W4411952096","https://openalex.org/W4412593989","https://openalex.org/W4414274541","https://openalex.org/W7160089460"],"related_works":["https://openalex.org/W7109961825","https://openalex.org/W7122485009","https://openalex.org/W7160089460","https://openalex.org/W4416324597","https://openalex.org/W7131655196","https://openalex.org/W7221886364","https://openalex.org/W4390662601","https://openalex.org/W4402278251","https://openalex.org/W4416817438","https://openalex.org/W4312545907"],"abstract_inverted_index":{"Background:":[0],"Respiratory":[1],"syncytial":[2],"virus":[3],"(RSV)":[4],"infects":[5],"nearly":[6],"all":[7],"children":[8],"under":[9],"two":[10],"years,":[11],"causing":[12],"mild":[13],"lower":[14,162],"respiratory":[15],"tract":[16],"infections":[17],"(LRTIs)":[18],"although":[19],"serious":[20],"disease,":[21],"mortality":[22],"and":[23,36,63,78,96,110,118,123,142,152,161,184,204,225,233,250,258,266],"long-term":[24],"recurrent":[25],"wheezing":[26],"can":[27],"also":[28,210],"occur.":[29],"Objectives:":[30],"This":[31],"study":[32],"evaluates":[33],"the":[34,114,236],"health":[35],"economic":[37],"impact":[38,115],"of":[39,87,116,130,138,149,256],"various":[40],"RSV":[41,76,92,168,261],"prevention":[42,262],"strategies":[43],"(monoclonal":[44],"antibodies":[45],"[mAb]":[46],"such":[47],"as":[48],"clesrovimab,":[49],"nirsevimab,":[50,203,224],"palivizumab":[51],"[high":[52],"risk":[53],"infants":[54,60,88,127],"only]":[55],"or":[56],"maternal":[57,133,187,207,230],"vaccination)":[58],"in":[59,61,94,264],"England":[62,95,265],"Wales.":[64,97,267],"Design:":[65],"A":[66],"previously":[67],"published":[68],"decision":[69],"tree":[70],"model":[71],"was":[72],"adapted":[73],"to":[74,112,156,166,218,223,229,244,253],"estimate":[75],"LRTIs":[77],"associated":[79],"costs":[80,111,141,164,213,251],"over":[81],"one":[82],"year":[83],"among":[84],"a":[85],"cohort":[86],"entering":[89],"their":[90],"first":[91],"season":[93],"Methods:":[98],"Clinical":[99],"trial":[100],"data":[101],"were":[102,144,196,235],"used":[103],"for":[104],"efficacy":[105],"inputs":[106],"alongside":[107,132],"country-specific":[108],"epidemiology":[109],"assess":[113],"year-round":[117],"seasonal":[119],"mAb":[120],"programs":[121],"(without":[122],"with":[124,151],"catch-up":[125,154],"[for":[126],"born":[128],"out":[129],"season])":[131],"vaccination.":[134,208,231],"Deterministic":[135],"sensitivity":[136],"analyses":[137],"incremental":[139],"treatment":[140,163,212],"QALYs":[143],"performed.":[145],"Results:":[146],"Seasonal":[147],"administration":[148],"clesrovimab":[150,173,195],"without":[153],"led":[155],"fewer":[157],"RSV-associated":[158,247],"LRTI":[159],"cases":[160,176],"compared":[165,217,222,228,252],"other":[167],"intervention":[169],"strategies.":[170],"Without":[171],"catch-up,":[172,190],"reduced":[174,211],"RSV-LRTI":[175,191],"by":[177,194,214],"18%-27%":[178],"versus":[179,182,186,199,202,206],"palivizumab,":[180,200,219],"3%-4%":[181],"nirsevimab":[183],"2%-13%":[185],"vaccine.":[188],"With":[189],"outcomes":[192,249],"reductions":[193],"greater:":[197],"60%-70%":[198],"14%-20%":[201],"43%-54%":[205],"It":[209],"\u00a337.0":[215],"million":[216,221,227],"\u00a34.0":[220],"\u00a326.0":[226],"Coverage":[232],"efficacies":[234],"most":[237],"influential":[238],"parameters.":[239],"Conclusions:":[240],"Clesrovimab":[241],"is":[242],"projected":[243],"substantially":[245],"reduce":[246],"clinical":[248],"both":[254],"standard":[255],"care":[257],"potential":[259],"new":[260],"measures":[263]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-09-18T00:00:00"}